Table 3 Associations Between Parameters and Clinicopathological Factors
Variables | dNLR | LDH | LNI | ||||||
|---|---|---|---|---|---|---|---|---|---|
H | L | P | H | L | P | H LNI(1) + (2) | L | P | |
Age (years) | |||||||||
  < 60 | 12 | 31 |  | 17 | 26 |  | 23 | 20 |  |
  ≥ 60 | 3 | 5 | 0.585 | 4 | 4 | 0.581 | 4 | 4 | 0.856 |
ECOG PS | |||||||||
 0 | 6 | 24 |  | 11 | 19 |  | 13 | 17 |  |
  ≥ 1 | 9 | 12 | 0.078 | 10 | 11 | 0.434 | 14 | 7 | 0.1 |
Menstrual status | |||||||||
 Menopause | 10 | 29 |  | 15 | 24 |  | 18 | 21 |  |
 Non-menopause | 5 | 7 | 0.287 | 6 | 6 | 0.478 | 9 | 3 | 0.08 |
CTCAE grades | |||||||||
  ≤ 2 | 12 | 26 |  | 18 | 20 |  | 23 | 15 |  |
  > 2 | 3 | 10 | 0.561 | 3 | 10 | 0.125 | 4 | 9 | 0.064 |
Treatment lines | |||||||||
  < 2 | 10 | 22 |  | 13 | 19 |  | 17 | 15 |  |
  ≥ 2 | 5 | 14 | 0.708 | 8 | 11 | 0.917 | 10 | 9 | 0.973 |
Brain metastases | |||||||||
 No | 14 | 27 |  | 15 | 26 |  | 21 | 20 |  |
 Yes | 1 | 9 | 0.133 | 6 | 4 | 0.177 | 6 | 4 | 0.618 |
Liver metastases | |||||||||
 No | 8 | 16 |  | 9 | 15 |  | 12 | 12 |  |
 Yes | 7 | 20 | 0.562 | 12 | 15 | 0.615 | 15 | 12 | 0.692 |
Anti-HER2 treatment | |||||||||
 Yes | 13 | 28 |  | 18 | 23 |  | 23 | 18 |  |
 No | 2 | 8 | 0.466 | 3 | 7 | 0.423 | 4 | 6 | 0.360 |
BMC status | |||||||||
 De novo | 0 | 5 |  | 2 | 3 |  | 2 | 3 |  |
 Recurrent | 15 | 31 | 0.129 | 19 | 27 | 0.955 | 25 | 21 | 0.542 |
HER2 status | |||||||||
 HER2(IHC2+)FISH(+) | 3 | 3 |  | 3 | 3 |  | 3 | 3 |  |
 HER2(IHC3+) | 12 | 33 | 0.239 | 18 | 27 | 0.64 | 24 | 21 | 0.878 |
HR status | |||||||||
 Negative | 5 | 24 |  | 11 | 18 |  | 12 | 17 |  |
 Positive | 10 | 12 | 0.029 | 10 | 12 | 0.589 | 15 | 7 | 0.058 |
Number of transfers | |||||||||
  ≤ 2 | 2 | 7 |  | 3 | 6 |  | 4 | 5 |  |
  > 2 | 13 | 29 | 0.602 | 18 | 24 | 0.598 | 23 | 19 | 0.574 |
Prior surgery | |||||||||
 No | 0 | 5 |  | 2 | 3 |  | 2 | 3 |  |
 Yes | 15 | 31 | 0.129 | 19 | 27 | 0.955 | 25 | 21 | 0.542 |